These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33073917)

  • 1. Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma.
    Ahn D; Lee GJ; Sohn JH; Lee JE
    Cancer Med; 2020 Dec; 9(24):9256-9265. PubMed ID: 33073917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
    Ueki Y; Ohshima S; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Ohtaki K; Saijo K; Tanaka R; Togashi T; Sato Y; Takano S; Omata J; Takahashi N; Okabe R; Horii A
    Int J Clin Oncol; 2024 Jan; 29(1):20-26. PubMed ID: 37843751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
    Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
    Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary concurrent chemoradiation therapy with triweekly cisplatin as a standard protocol in patients aged ≥65 years with head and neck squamous cell carcinoma.
    Ahn D; Kwak JH; Lee GJ; Sohn JH; Lee JE
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e239-e247. PubMed ID: 36178306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
    Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
    Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
    Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
    Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
    Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
    Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
    Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
    Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
    Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
    Borel C; Sun XS; Coutte A; Bera G; Sire C; Zanetta S; Alfonsi M; Janoray G; Chatellier T; Garcia-Ramirez M; Gherga E; Hammoud Y; Burgy M; Etienne-Selloum N; Pechery A; Girard-Calais MH; Velten M; Pignon JP; Wanneveich M; Bourhis J
    Radiother Oncol; 2024 Aug; 197():110329. PubMed ID: 38768714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
    Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
    Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
    Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
    Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.
    Lee SY; Choi YS; Song IC; Park SG; Keam B; Yang YJ; Song EK; Lee HJ; Cho SH; Shim H; Park KU; Lee KH; Jo DY; Jo IS; Yun HJ;
    Medicine (Baltimore); 2018 May; 97(21):e10778. PubMed ID: 29794758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control.
    Belgioia L; Bacigalupo A; Missale F; Vecchio S; Chiola I; Callegari S; Verzanini E; Peretti G; Corvò R
    Med Oncol; 2019 Mar; 36(5):42. PubMed ID: 30927146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
    Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
    Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy.
    Morse RT; Ganju RG; Neeranjun R; Gan GN; Cao Y; Neupane P; Kakarala K; Shnayder Y; Lominska CE
    Chemotherapy; 2023; 68(1):35-43. PubMed ID: 35882207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation.
    Rühle A; Weymann M; Behrens M; Marschner S; Haderlein M; Fabian A; Senger C; Dickstein DR; Kraft J; von der Grün J; Chen E; Aquino-Michaels T; Domschikowski J; Bickel A; Altay-Langguth A; Kalinauskaite G; Lewitzki V; Bonomi M; Blakaj DM; Jhawar SR; Baliga S; Barve R; Ferentinos K; Zamboglou C; Schnellhardt S; Haehl E; Spohn SKB; Kuhnt T; Zöller D; Guckenberger M; Budach V; Belka C; Bakst R; Mayer A; Schmidberger H; Grosu AL; Balermpas P; Stromberger C; Nicolay NH
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1282-1293. PubMed ID: 37914144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
    Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
    Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Limaye S; Damjanov N; Di Stefano J; Ciunci C; Genden EM; Wisnivesky JP; Ferrandino R; Mamtani R; Langer CJ; Cohen RB; Sigel K
    J Natl Cancer Inst; 2019 May; 111(5):490-497. PubMed ID: 30239887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.